Evidence map›Paper›PMID 31654156›Full record

ArticleWiener medizinische Wochenschrift (1946)2020

Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.

Peter Peichl, Rieke Alten, Mauro Galeazzi, Hanns-Martin Lorenz, Hubert Nüßlein, Federico Navarro, Yedid Elbez, Melanie Chartier, Roland Hackl, Christiane Rauch and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Wiener medizinische Wochenschrift (1946), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02109666 (Long Term Experience With Abatacept in Routine Clinical Practice), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02109666 completednot on this map

Long Term Experience With Abatacept in Routine Clinical Practice

TypeobservationalSponsorBristol-Myers SquibbRan2008 to 2016Enrolled2,364ConditionsRheumatoid ArthritisArmsAbatacept
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Peter PeichlEvangelisches Krankenhaus Wien, Hans-Sachs-Gasse 10-12, 1180, Vienna, Austria. p.peichl@ekhwien.at.ORCID http://orcid.org/0000-0002-1090-7904
Rieke AltenSchlosspark-Klinik University Medicine, Berlin, Germany.
Mauro GaleazziUniversity of Siena, Siena, Italy.
Hanns-Martin LorenzUniversity Hospital, Heidelberg, Germany.
Hubert NüßleinUniversity of Erlangen-Nuremberg, Nuremberg, Germany.
Federico NavarroUniversity Hospital Virgen Macarena, Seville, Spain.
Yedid ElbezExcelya, Boulogne-Billancourt, France.
Melanie ChartierBristol-Myers Squibb, Rueil-Malmaison, France.
Roland HacklBristol-Myers Squibb, Vienna, Austria.
Christiane RauchBristol-Myers Squibb, Munich, Germany.
Sean E ConnollyBristol-Myers Squibb, Princeton, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was a 2-year international observational study of patients with moderate to severe rheumatoid arthritis.

methodsBaseline characteristics, abatacept retention rates, and clinical outcomes were compared by treatment line in the Austrian cohort of ACTION.

resultsOf 100 patients enrolled in Austria, 98 (98.0%) were evaluable: 33/98 (33.7%) biologic naïve and 65/98 (66.3%) with ≥1 prior biologic failure. At baseline, biologic-naïve patients had shorter disease duration and lower concomitant corticosteroid use than biologic-failure patients. Overall crude abatacept retention rate was 60.5% and retention rate was higher in biologic-naïve (65.1%) versus biologic-failure (58.0%) patients. Good/moderate EULAR (European League Against Rheumatism) response rates were 85.7% in biologic-naïve and 100% in biologic-failure patients.

conclusionsIn the Austrian cohort of ACTION, overall abatacept retention at 2 years was high, with higher retention rates in patients receiving abatacept as an earlier treatment line. Good/moderate EULAR response rate was higher in biologic-failure than in biologic-naïve patients.

Indexed as

AbataceptAntirheumatic AgentsArthritis, RheumatoidAustriaHumansTreatment OutcomeAbataceptAntirheumatic AgentsClinical responseCostimulation blockadeDMARDReal world dataRetention rate

Identifiers

PMID31654156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.